California State Teachers Retirement System Lowers Holdings in Stryker Corporation $SYK

California State Teachers Retirement System lowered its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 2.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 518,979 shares of the medical technology company's stock after selling 14,585 shares during the quarter. California State Teachers Retirement System owned approximately 0.14% of Stryker worth $163,395,348 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Sankala Group LLC bought a new position in Stryker in the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker during the 4th quarter valued at $26,000. Gables Capital Management Inc. purchased a new position in shares of Stryker in the second quarter worth $25,000. Kilter Group LLC purchased a new stake in shares of Stryker in the second quarter worth $25,000. Finally, Highland Investment Advisors LLC purchased a new position in shares of Stryker during the 2nd quarter valued at about $25,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

NYSE SYK traded down $0.61 during trading on Tuesday, hitting $281.25. 1,094,350 shares of the stock traded hands, compared to its average volume of 2,410,385. The firm has a 50-day simple moving average of $323.77 and a 200-day simple moving average of $325.37. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $107.88 billion, a P/E ratio of 29.20, a price-to-earnings-growth ratio of 1.73 and a beta of 0.76. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $392.55.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the company posted $3.13 EPS. The business's quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.3%. Stryker's dividend payout ratio is 36.48%.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research analyst reports. Leerink Partners dropped their price target on Stryker from $410.00 to $407.00 and set an "outperform" rating on the stock in a research note on Friday, June 5th. UBS Group assumed coverage on Stryker in a research note on Tuesday, July 28th. They set a "buy" rating and a $400.00 target price for the company. BMO Capital Markets restated an "outperform" rating and issued a $317.00 target price on shares of Stryker in a report on Wednesday, September 9th. Citizens Jmp lowered their price target on Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a research note on Monday, August 3rd. Finally, Piper Sandler dropped their price objective on shares of Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Eighteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $380.40.

Insiders Place Their Bets

In related news, insider Debra King sold 826 shares of the company's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda Stryker sold 300,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker's principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.